| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:46 | SHORT SQUEEZE bei Gerresheimer? WACHSEN Bayer und MustGrow bald gemeinsam? | 1.218 | ESG-Aktien.de | Während die Börse den Iran-Krieg und steigende Energiepreise verdauen, zieht plötzlich die Aktie von Gerresheimer spürbar an. News gibt es keine. Ist ein Short Squeeze möglich? Leerverkäufer hatten... ► Artikel lesen | |
| 14:06 | PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights | 654 | GlobeNewswire (Europe) | Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt... ► Artikel lesen | |
| 13:06 | Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 595 | GlobeNewswire (Europe) | JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated... ► Artikel lesen | |
| 08:42 | RBC stuft Sartorius Stedim Biotech auf 'Outperform' | 409 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Sartorius Stedim zwar von 240 auf 210 Euro gesenkt, die Aktien aber nach ihrer Underperformance wieder von "Sector Perform"... ► Artikel lesen | |
| 14:06 | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update | 336 | GlobeNewswire (Europe) | GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 08:27 | NurExone Biologic: Einzigartige Erfolge mit ExoPTEN! | bullVestor | |||
| 16:18 | EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug | 290 | AFX News | PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19... ► Artikel lesen | |
| 14:36 | Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 288 | GlobeNewswire (Europe) | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total... ► Artikel lesen | |
| 13:06 | AtaiBeckley Inc.: AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update | 288 | GlobeNewswire (Europe) | Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track... ► Artikel lesen | |
| 16:30 | Servier; Day One Biopharmaceuticals: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 286 | PR Newswire | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents... ► Artikel lesen | |
| 16:06 | Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet | 269 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The biotech sector delivered a mix of regulatory milestones, strategic deals, corporate restructuring and clinical trial developments across therapeutic areas... ► Artikel lesen | |
| 20:28 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.03.2026 | 222 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 06.03.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.03.2026ISIN NameDE000DG4T770 DZ... ► Artikel lesen | |
| Do | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | 218 | GlobeNewswire (Europe) | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| 14:06 | Artelo Biosciences Announces Reverse Stock Split | 214 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling... ► Artikel lesen | |
| 09:20 | ANALYSE-FLASH: RBC hebt Sartorius Stedim Biotech auf 'Outperform' - Kaufchance | 197 | dpa-AFX | NEW YORK (dpa-AFX Broker) - Die kanadische Bank RBC hat das Kursziel für Sartorius Stedim zwar von 240 auf 210 Euro gesenkt, die Aktien aber nach ihrer Underperformance wieder von "Sector Perform"... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 49,800 | 2,49 | +5,00 % | 2,25 | 23.03.2026 | |
| CSL | 88,29 | 2,60 | +2,94 % | 1,84 | 10.03.2026 | |
| AMGEN | 316,00 | 8,12 | +2,57 % | 2,52 | 13.02.2026 | |
| NOVONESIS | 48,790 | 0,87 | +1,78 % | 4,25 | 20.03.2026 | |
| GENUS | 31,000 | 0,38 | +1,23 % | 0,11 | 05.03.2026 | |
| STRYKER | 314,60 | 2,98 | +0,95 % | 0,88 | 31.03.2026 | |
| BIO-TECHNE | 48,600 | 0,27 | +0,56 % | 0,08 | 13.02.2026 | |
| BRUKER | 31,600 | 0,17 | +0,54 % | 0,05 | 23.03.2026 | |
| REGENERON PHARMACEUTICALS | 652,80 | 3,02 | +0,46 % | 0,94 | 20.02.2026 | |
| SARTORIUS STEDIM BIOTECH | 166,30 | 0,69 | +0,41 % | 0,69 | 31.03.2026 |